Skip to main content

Table 3 2-hPG, FPG and HbAlc before and after the intervention across different groups

From: Effect of transcutaneous auricular vagus nerve stimulation on impaired glucose tolerance: a pilot randomized study

 

Ta-VNS

Sham taVNS

No-treatment

2hPG Baseline

9.7 (1.2)

9.1(1.2)

9.3 (1.1)

2hPG 6-weeks

7.3 (1.8)**

8.0 (1.6)**

9.5 (1.9)

2hPG 12-weeks

7.5 (1.3)**

8.0 (1.4)**

10.0 (2.7)

FPG Baseline

6.2 (0.6)

6.3 (0.5)

6.5 (0.3)

FPG 6-weeks

5.9 (0.8)**

6.2 (0.8)

6.6 (0.8)

FPG 12-weeks

5.7 (0.6)**

6.2 (0.8)

6.9 (1.2)

HbAlc Baseline

6.3 (0.5)

6.2 (0.6)

6.2 (0.4)

HBAlc 12-weeks

6.1 (0.4)*

6.0 (0.4)*

6.3 (0.6)

BMI Baseline

24.5 (3.5)

23.9 (2.6)

25.7 (3.4)

BMI 12-weeks

24.1 (3.3)

23.5 (2.6)

25.4 (3.0)

  1. Compared to No-treatment group, *p < 0.05, **p < 0.01.
  2. All values are presented as mean (SD).